ADC Therapeutics SA (ADCT) - Total Assets
Based on the latest financial reports, ADC Therapeutics SA (ADCT) holds total assets worth $289.76 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is ADC Therapeutics SA's book value for net asset value and shareholders' equity analysis.
ADC Therapeutics SA - Total Assets Trend (2016–2024)
This chart illustrates how ADC Therapeutics SA's total assets have evolved over time, based on quarterly financial data.
ADC Therapeutics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
ADC Therapeutics SA's total assets of $289.76 Million consist of 95.5% current assets and 4.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.9% |
| Accounts Receivable | $20.32 Million | 6.3% |
| Inventory | $18.39 Million | 5.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how ADC Therapeutics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ADC Therapeutics SA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ADC Therapeutics SA's current assets represent 95.5% of total assets in 2024, a decrease from 97.5% in 2016.
- Cash Position: Cash and equivalents constituted 77.9% of total assets in 2024, down from 92.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.3% of total assets.
ADC Therapeutics SA Competitors by Total Assets
Key competitors of ADC Therapeutics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $5.99 Billion |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
ADC Therapeutics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.63 | 4.92 | 11.14 |
| Quick Ratio | 4.34 | 4.68 | 10.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $225.10 Million | $265.33 Million | $410.01 Million |
ADC Therapeutics SA - Advanced Valuation Insights
This section examines the relationship between ADC Therapeutics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.58 |
| Latest Market Cap to Assets Ratio | 1.35 |
| Asset Growth Rate (YoY) | -9.2% |
| Total Assets | $321.98 Million |
| Market Capitalization | $433.57 Million USD |
Valuation Analysis
Above Book Valuation: The market values ADC Therapeutics SA's assets above their book value (1.35x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ADC Therapeutics SA's assets decreased by 9.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ADC Therapeutics SA (2016–2024)
The table below shows the annual total assets of ADC Therapeutics SA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $321.98 Million | -9.25% |
| 2023-12-31 | $354.78 Million | -27.72% |
| 2022-12-31 | $490.86 Million | -20.57% |
| 2021-12-31 | $617.97 Million | +20.30% |
| 2020-12-31 | $513.69 Million | +273.10% |
| 2019-12-31 | $137.68 Million | -8.55% |
| 2018-12-31 | $150.56 Million | -44.64% |
| 2017-12-31 | $271.95 Million | +75.36% |
| 2016-12-31 | $155.08 Million | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the Chi… Read more